๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bangalore
Clinical trial register · India

Clinical Trials in Bangalore

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca39 Eli Lilly and Company15 Novartis Pharmaceuticals11 Novo Nordisk A/S10 Janssen Research & Development, LLC9
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
193 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
Biogen
Phase 3
454
Hyderabad, Raipur, Ahmedabad, Nadiฤd, Bangalore, Kozhikode, Trivandrum, Mumbai
2025-05-08
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Ahmedabad, Bangalore, Binnฤguri, Dehradun, Delhi, Hyderabad, Mumbai, Nashik
2025-05-06
Recruiting
Development, Validation and Evaluation of a Deprescribing Tool
NCT07114094Elderly
Indian Council of Medical Research
Not applicable
1,650
Bangalore, Bhopal
2025-05-01
Not yet open
A Study on the Safety and Effectiveness of the Mantraโ„ข Surgical Robotic System for Soft Tissue Surgeries
NCT06974955Soft Tissue Surgeries
Sudhir Srivastava Innovations Pvt. Ltd.
Observational
365
Bangalore
2025-05
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
Eli Lilly and Company
Phase 3
974
Bangalore, Bhubaneswar, New Delhi, Ulhasnagar
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
Eli Lilly and Company
Phase 3
487
Bangalore, Bhubaneswar, New Delhi, Ulhasnagar
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
Eli Lilly and Company
Phase 3
487
Bangalore, Bhubaneswar, New Delhi, Ulhasnagar
2025-04-30
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Immutep S.A.S.
Phase 3
756
Bangalore, Bhubaneswar, Chennai, Kolkata, New Delhi, Thane, Thiruvananthapuram, Varanasi
2025-03-21
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Ahmedabad, Ajmer, Bangalore, Belagavi, Dehradun, Delhi, Gurgaon, Hyderabad
2025-03-14
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Bangalore, Belagavi, Hyderabad, Kolkata, Madurai, Mumbai, New Delhi, Pune
2025-03-03
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Ansฤrinagar, Bangalore, Delhi, Hyderabad, Kolkata, Mumbai, Varanasi
2025-03-01
Not yet open
The Effect of Cosmetic Products on Skin Brightening
NCT06899321Skin Brightening
Unilever R&D
Not applicable
34
Bangalore
2025-03
By invitation
Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia
NCT07163260Haemophilia
Novo Nordisk A/S
Observational
244
Bangalore
2025-01-31
Recruiting
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
NCT06755450Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited
Phase 1
40
Vadodara, Jhajjar, Bangalore, Aurangabad, Nagpur, Pune, Satara, Thane
2025-01-15
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
Raipur, Mumbai, Bangalore, Gujarat, Maharashtra, New Delhi
2025-01-10
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
Pfizer
Phase 3
1,035
Surat, Gurugram, Bangalore, Mumbai, Nashik, Pune, Thane, New Delhi
2025-01-06
Active, closed
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
NCT06429761BREAST CANCER
AstraZeneca
Phase 4
100
Bangalore, Delhi, Kochi, Mumbai, New Delhi, Pune, Varanasi
2025-01-02
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
GlaxoSmithKline
Phase 3
520
Ahmedabad, Bangalore, Hyderabad, Kolkata, Pune, Sushrut Hospital and Research
2024-12-16
Recruiting
Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.
NCT06201611Diabetic Neuropathy Peripheral
St. John's Research Institute
Phase 2/3
120
Bangalore
2024-11-15
Recruiting
EASi-KIDNEYโ„ข (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
Boehringer Ingelheim
Phase 3
11,000
Bangalore, Bathinda, Bhubaneswar, Bilฤspur, Chandigarh, Chennai, Dwฤrka, Faridabad
2024-08-30
Recruiting
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
NCT06831370Hodgkin Lymphoma
Takeda
Phase 4
124
Vijayawada, Guwahati, Surat, Bangalore, Puducherry, Nashik, Navi Mumbai, Pune
2024-08-28
Recruiting
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
NCT07755397NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
Jubilant Therapeutics India Limited
Phase 1
30
Surat, Bangalore, Mumbai, Nashik, Thane, New Delhi
2024-08-26
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746Heart Failure
Colorado Prevention Center
Phase 3
1,500
Ahmedabad, Bangalore, Nagpur, New Delhi
2024-07-09
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
Raipur, Nadiฤd, Vadodara, Bangalore, Pune, Sambhajinagar, New Delhi, Patparganj
2024-07-02
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Hyderabad, Bangalore, Mangalore, Nashik, Pune
2024-06-25
Rows per page Showing 51–75 of 193
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/bangalore

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.